ResMed (RMD)
(Delayed Data from NYSE)
$183.42 USD
-0.36 (-0.20%)
Updated Apr 25, 2024 04:00 PM ET
After-Market: $198.00 +14.58 (7.95%) 4:40 PM ET
2-Buy of 5 2
C Value C Growth F Momentum D VGM
Income Statements
Fiscal Year end for ResMed Inc falls in the month of June .
All items in Millions except EPS data.
6/30/23 | 6/30/22 | 6/30/21 | 6/30/20 | 6/30/19 | |
---|---|---|---|---|---|
Sales | 4,223 | 3,578 | 3,197 | 2,957 | 2,607 |
Cost Of Goods | 1,867 | 1,554 | 1,358 | 1,239 | 1,070 |
Gross Profit | 2,356 | 2,024 | 1,839 | 1,718 | 1,537 |
Selling & Adminstrative & Depr. & Amort Expenses | 1,224 | 1,024 | 935 | 908 | 957 |
Income After Depreciation & Amortization | 1,132 | 1,000 | 904 | 810 | 579 |
Non-Operating Income | 17 | -17 | 4 | -36 | -24 |
Interest Expense | 47 | 22 | 24 | 40 | 36 |
Pretax Income | 1,102 | 960 | 884 | 733 | 519 |
Income Taxes | 204 | 181 | 409 | 111 | 114 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | 898 | 779 | 475 | 622 | 405 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | 898 | 779 | 475 | 622 | 405 |
Depreciation Footnote | 6/30/23 | 6/30/22 | 6/30/21 | 6/30/20 | 6/30/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 1,329 | 1,194 | 1,095 | 991 | 730 |
Depreciation & Amortization (Cash Flow) | 198 | 194 | 192 | 181 | 151 |
Income After Depreciation & Amortization | 1,132 | 1,000 | 904 | 810 | 579 |
Earnings Per Share Data | 6/30/23 | 6/30/22 | 6/30/21 | 6/30/20 | 6/30/19 |
---|---|---|---|---|---|
Average Shares | 147.46 | 147.04 | 146.45 | 145.65 | 144.48 |
Diluted EPS Before Non-Recurring Items | 6.44 | 5.79 | 5.33 | 4.76 | 3.64 |
Diluted Net EPS (GAAP) | 6.09 | 5.30 | 3.24 | 4.27 | 2.80 |
Fiscal Year end for ResMed Inc falls in the month of June .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 1,162.80 | 1,102.32 | 1,122.06 | 1,116.90 |
Cost Of Goods | NA | 515.87 | 502.26 | 504.67 | 499.15 |
Gross Profit | NA | 646.93 | 600.06 | 617.39 | 617.75 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 371.84 | 311.06 | 332.94 | 317.09 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | 275.09 | 289.00 | 284.45 | 300.66 |
Non-Operating Income | NA | -1.84 | -1.85 | 16.48 | 3.67 |
Interest Expense | NA | 13.81 | 14.96 | 14.94 | 14.96 |
Pretax Income | NA | 259.45 | 272.19 | 276.80 | 289.38 |
Income Taxes | NA | 50.65 | 52.77 | 47.14 | 56.88 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | 208.80 | 219.42 | 229.66 | 232.50 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | 208.80 | 219.42 | 229.66 | 232.50 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 147.55 | 147.49 | 147.55 | 147.40 |
Diluted EPS Before Non-Recurring Items | NA | 1.88 | 1.64 | 1.60 | 1.68 |
Diluted Net EPS (GAAP) | NA | 1.42 | 1.49 | 1.55 | 1.58 |